Common currently available anti-T2DM drugs include high-dose glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual/triple-hormone (GLP-1, glucose-dependent insulinotropic polypeptide (GIP) and glucagon) agonists, all of which have been shown to cause varying degrees of weight loss. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.